HPV Vaccination in Young Girls from Developing Countries: What Are the Barriers for Its Implementation? A Systematic Review
- 1 School of Medicine, University of Minho, Braga, Portugal
- 2 School of Medicine, University of Minho, Braga, Portugal
- 3 Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
- 4 ICVS/3B’s-PT Government Associate Laboratory, Braga/Guimarães, Portugal
- 5 Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
- 6 Medical Laboratory of Medical Investigation (LIM) 14, Department of Pathology, Medical School, University of São Paulo, São Paulo, Brazil
Abstract
Cervical cancer is the second most common cancer in women living in developing countries that account high HPV incidence and mortality rates. Vaccinating girls between 9 and 14 years old is supposed to be the most cost-effective public health approach against cervical cancer. This systematic review aims to assess the application and coverage of the HPV vaccine in developing countries and identify the main challenges for the introduction of the vaccine in these settings. Eligible studies were selected according to the defined inclusion and exclusion criteria. To determine the quality of the studies was employed the STROBE checklist. This review included seven studies, encompassing the analysis of 19 countries and 112,116 girls aged from 9 to 18 years old. The coverage of HPV vaccination ranged from 13.8% to 107.4%, with most of the programs having more than 60% of coverage, which reflects a high percentage of vaccinated girls. The main challenges were lack of knowledge and worries about the vaccine, insufficient financial resources and staff workers, lack of community involvement and dissemination of important information about HPV. In developing countries that implemented the HPV vaccine, high coverage rates were achieved, despite sociocultural, economic and political challenges. In the future, studies that analyze the coverage rates after the elimination of the barriers and the repercussions on the mortality rates should be conducted, so that more developing countries have the opportunity to efficiently implement the vaccine.
- World Health Organization (2019) Human Papillomavirus (HPV) and Cervical Cancer. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
- Arbyn, M., Weiderpass, E., Bruni, L., Sanjosé, S., Saraiya, M., Ferlay, J. and Bray, F. (2020) Estimates of Incidence and Mortality of Cervical Cancer in 2018: A Worldwide Analysis. The Lancet Global Health, 8, e191-e203. https://doi.org/10.1016/S2214-109X(19)30482-6
- Lamontagne, D.S., Bloem, P.J., Brotherton, J.M., Gallagher, K.E., Badiane, O. and Ndiaye, C. (2017) Progress in HPV Vaccination in Low- and Lower-Middle-Income Countries. International Journal of Gynecology & Obstetrics, 138, 7-14. https://doi.org/10.1002/ijgo.12186
- Expanded Programme on Immunization (EPI) of the Department of Immunization, Vaccines and Biologicals of World Health Organization (2016) Guide to Introducing HPV Vaccine into National Immunization Programmes.
- Gallagher, K.E., Howard, N., Kabakama, S., Mounier-Jack, S., Burchett, H.E., Lamontagne, D.S. and Watson-Jones, D. (2017) Human Papillomavirus (HPV) Vaccine Coverage Achievements in Low and Middle-Income Countries 2007-2016. Papillomavirus Research, 4, 72-78. https://doi.org/10.1016/j.pvr.2017.09.001
- Gallagher, K., Lamontagne, D. and Watson-Jones, D. (2018) Status of HPV Vaccine Introduction and Barriers to Country Uptake. Vaccine, 36, 4761-4767. https://doi.org/10.1016/j.vaccine.2018.02.003
- (2015) PRISMA Transparent Reporting of Systematic Reviews and Meta-Analyses. PRISMA Flow Diagram. http://prisma-statement.org/PRISMAStatement/FlowDiagram
- Nabirye, J., Okwi, L., Nuwematsiko, R., Kiwanuka, G., Muneza, F., Kamya, C.N. and Babirye, J. (2020) Health System Factors Influencing Uptake of Human Papilloma Virus (HPV) Vaccine among Adolescent Girls 9-15 Years in Mbale District, Uganda. BMC Public Health, 20, Article No. 17. https://doi.org/10.1186/s12889-020-8302-z
- Kisaakye, E., Namakula, J., Kihembo, C., Kisakye, A., Nsubuga, P. and Babirye, J.N. (2018) Level and Factors Associated with Uptake of Human Papillomavirus Infection Vaccine among Female Adolescents in Lira District, Uganda. Pan African Medical Journal, 31, 184. https://doi.org/10.11604/pamj.2018.31.184.14801
- Soi, C., Gimbel, S., Chilundo, B., Muchanga, V., Matsinhe, L. and Sherr, K. (2018) Human Papillomavirus Vaccine Delivery in Mozambique: Identification of Implementation Performance Drivers Using the Consolidated Framework for Implementation Research (CFIR). Implementation Science, 13, 151. https://doi.org/10.1186/s13012-018-0846-2